Canaccord Genuity Reiterates a 'Buy' on Amarin Corporation (AMRN); AMR101 Benefits Diabetics in ANCHOR
Tweet Send to a FriendGet Alerts AMRN Hot Sheet
Price: $6.78 -2.02%
Rating Summary:
9 Buy, 3 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 11 | Down: 18 | New: 13
Rating Summary:
9 Buy, 3 Hold, 0 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 11 | Down: 18 | New: 13
Trade AMRN Now!
Canaccord Genuity reiterates a 'Buy' on Amarin Corporation (NASDAQ: AMRN) price target of $25.00.
Analyst, Ritu Baral, said, "Reiterate rating and price target on AMR101 commercial, partnering potential. We think AMR101, Amarin’s 96% EPA omega-3, will be approved for hypertriglyceridemia in H2/12, likely around its July 26 PDUFA date, with a broad label that will include ANCHOR trial mixed dyslipidemia data. We expect additional IP and business development progress in H2/12."
"We strongly believe AMR101 will be approved soon. We see the AMR101 clinical/CMC package as strong. Based on FOIA feedback, we think no new AMR101 plant inspections were needed for CMC."
For an analyst ratings summary and ratings history on Amarin Corporation click here. For more ratings news on Amarin Corporation click here.
Shares of Amarin Corporation closed at $11.30 yesterday, with a 52 week range of $5.99-$16.26.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Analyst, Ritu Baral, said, "Reiterate rating and price target on AMR101 commercial, partnering potential. We think AMR101, Amarin’s 96% EPA omega-3, will be approved for hypertriglyceridemia in H2/12, likely around its July 26 PDUFA date, with a broad label that will include ANCHOR trial mixed dyslipidemia data. We expect additional IP and business development progress in H2/12."
"We strongly believe AMR101 will be approved soon. We see the AMR101 clinical/CMC package as strong. Based on FOIA feedback, we think no new AMR101 plant inspections were needed for CMC."
For an analyst ratings summary and ratings history on Amarin Corporation click here. For more ratings news on Amarin Corporation click here.
Shares of Amarin Corporation closed at $11.30 yesterday, with a 52 week range of $5.99-$16.26.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Analyst Sees Potential for Omeros' (OMER) OMS824 as FDA Gives Clearance
- Wells Fargo Boosts Price Target on Pandora (P), Maintains Outperform
- Toll Bros. (TOL) Estimates/PT Raised at Compass Point
Create E-mail Alert Related Categories
Analyst Comments, FDA
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
